WHO suggests that women living with HIV who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ or treated as a result of a positive screening test be retested in 12 months with HPV DNA testing when available rather than with cytology or inspection of the cervix with acetic acid (VIA) or co-testing, and, if negative, be retested again at 12 months and, if negative again, move to the recommended screening interval